GU Cancers 2021 | ctDNA abnormalities in prostate cancer: distinctions in AA versus Ca patients
Pedro Barata, MD, MSc, Tulane University School of Medicine, New Orleans, LA, gives a summary of recent findings on circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer based on a study of real-world data. The study analyzed data from 361 patients with advanced prostate cancer. The most commonly detected pathogenic genomic alterations were in TP53, AR, PI3KCA, RAF, NF1 and MYC. Liquid biopsy of ctDNA was determined to be useful for the genetic characterization of advanced prostate cancer. The study also highlighted distinctions in the molecular phenotype of African American (AA) versus Caucasian (Ca) prostate cancer patients with clinical implications. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Pedro Barata, MD, MSc, has served in a consulting or advisory role for Bayer, Bristol-Myers Squibb, Pfizer, EMD Serono, Eisai, Caris Life Sciences, Clovis, and Dendreon; and has received institutional research funding from Blue Earth Diagnostics, AstraZeneca and Merck.
